FDA approves muscle-targeted SMA therapy
The therapy inhibits myostatin signaling and is used with survival motor neuron 2-targeted treatment.
-
By
-
Kathryn Wighton
-
September 14, 2026
-
Clinical Scorecard: FDA approves muscle-targeted SMA therapy
At a Glance
| Category | Detail |
|---|
| Condition | Spinal Muscular Atrophy (SMA) |
| Key Mechanisms | Inhibition of myostatin signaling through binding to promyostatin and latent myostatin. |
| Target Population | Adult and pediatric patients aged 2 years and older receiving survival motor neuron 2-targeted treatment. |
| Care Setting | Clinical trial setting for SMA treatment. |
Key Highlights
- Apitegromab-mstn (Isembyld) approved for SMA treatment.
- Based on SAPPHIRE trial results with 188 patients aged 2 to 21 years.
- 10 mg/kg dosage showed significant improvement in motor function.
- 34% of patients on apitegromab had a 3-point improvement vs 14% on placebo.
- Common adverse reactions included upper respiratory infections and vomiting.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of SMA should be confirmed through genetic testing.
Management
- Apitegromab is recommended for patients receiving survival motor neuron 2-targeted treatment.
Monitoring & Follow-up
- Monitor for common adverse reactions such as infections and gastrointestinal symptoms.
Risks
- Fractures occurred in 9% of patients receiving apitegromab vs 2% on placebo.
Patient & Prescribing Data
Patients aged 2 years and older with 5q SMA.
Recommended dosage is 10 mg/kg administered every 4 weeks.
Clinical Best Practices
- Ensure patients are receiving background treatment with nusinersen or risdiplam.
- Regularly assess motor function using the Hammersmith Functional Motor Scale-Expanded.
Related Resources & Content
